| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8786235 | Clinical Oncology | 2018 | 6 Pages |
Abstract
The use of FOLFIRINOX in the general population has increased since 2011. Survival outcomes show a substantial efficacy-effectiveness gap between the pivotal Prodige 4/ACCORD 11 clinical trial and routine practice.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
S. Karim, J. Zhang-Salomans, J.J. Biagi, T. Asmis, C.M. Booth,